Evidence map›Paper›PMID 40623967›Full record

ArticleNature communications2025

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.

Nabih Maslah, Nina Kaci, Blandine Roux, Gabriela Alexe, Raphael Marie, Hélène Pasquer, Emmanuelle Verger, Rafael Daltro De Oliveira, Cécile Culeux, Bochra Mlayah and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Nabih Maslah *Université Paris Cité, APHP, Hôpital Saint-Louis, Laboratoire de Biologie Cellulaire, Paris, France.ORCID http://orcid.org/0000-0002-5553-462X
Nina Kaci *INSERM UMR 944, Institut de Recherche Saint-Louis, Paris, France.
Blandine Roux *INSERM UMR 944, Institut de Recherche Saint-Louis, Paris, France.
Gabriela AlexeDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5668-6297
Raphael MarieINSERM UMR 944, Institut de Recherche Saint-Louis, Paris, France.
Hélène PasquerINSERM UMR 944, Institut de Recherche Saint-Louis, Paris, France.
Emmanuelle VergerUniversité Paris Cité, APHP, Hôpital Saint-Louis, Laboratoire de Biologie Cellulaire, Paris, France.ORCID http://orcid.org/0000-0002-2773-2784
Rafael Daltro De OliveiraUniversité Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM, CIC 1427, Paris, France.
Cécile CuleuxINSERM UMR 944, Institut de Recherche Saint-Louis, Paris, France.
Bochra MlayahINSERM UMR 1131, Institut de Recherche Saint-Louis, Paris, France.
Nicolas GauthierUniversité Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM, CIC 1427, Paris, France.
Fanny GonzalesDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, USA.
Lin-Pierre ZhaoUniversité Paris Cité, APHP, Hôpital Saint-Louis, Département d'hématologie et d'Immunologie, Paris, France.ORCID http://orcid.org/0000-0001-5035-4470
Saravanan GanesanINSERM UMR 1131, Institut de Recherche Saint-Louis, Paris, France.ORCID http://orcid.org/0000-0002-5773-1715
Panhong GouINSERM UMR 1131, Institut de Recherche Saint-Louis, Paris, France.
Frank LingINSERM UMR 944, Institut de Recherche Saint-Louis, Paris, France.
Juliette Soret-DulphyUniversité Paris Cité, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM, CIC 1427, Paris, France.
Nathalie ParquetUniversité Paris Cité, APHP, Hôpital Saint-Louis, Département d'hématologie et d'Immunologie, Paris, France.
William VainchenkerUniversité Paris Cité, APHP, Hôpital Saint-Louis, Département d'hématologie et d'Immunologie, Paris, France.ORCID http://orcid.org/0000-0003-4705-202X
Emmanuel RaffouxUniversité Paris Cité, APHP, Hôpital Saint-Louis, Département d'hématologie et d'Immunologie, Paris, France.ORCID http://orcid.org/0000-0003-3925-7391
Rose Ann PaduaINSERM UMR 1131, Institut de Recherche Saint-Louis, Paris, France.
Stéphane GiraudierUniversité Paris Cité, APHP, Hôpital Saint-Louis, Laboratoire de Biologie Cellulaire, Paris, France.
Caroline MartyINSERM UMR 1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France.ORCID http://orcid.org/0000-0003-4350-2302
Isabelle PloINSERM UMR 1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Camille LobryINSERM UMR 944, Institut de Recherche Saint-Louis, Paris, France.ORCID http://orcid.org/0000-0003-0550-4921
Kimberly StegmaierDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0218-7895
Alexandre PuissantINSERM UMR 944, Institut de Recherche Saint-Louis, Paris, France.ORCID http://orcid.org/0000-0002-3997-9282
Jean-Jacques KiladjianINSERM UMR 1131, Institut de Recherche Saint-Louis, Paris, France.
Bruno CassinatUniversité Paris Cité, APHP, Hôpital Saint-Louis, Laboratoire de Biologie Cellulaire, Paris, France.ORCID http://orcid.org/0000-0002-6514-3905
Lina BenajibaINSERM UMR 944, Institut de Recherche Saint-Louis, Paris, France. lina.benajiba@inserm.fr.ORCID http://orcid.org/0000-0001-5440-1115

Funding

Integrating Transforming Approaches to Identify and Target New Vulnerabilities in CancerR35CA210030 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2016 to 2022
$7.3M
NCI NIH HHS R35 CA210030
6 · The paper itself

Abstract

JAK (Janus Kinase) inhibitors, such as ruxolitinib, were introduced a decade ago for treatment of myeloproliferative neoplasms (MPN). To evaluate ruxolitinib's impact on MPN clonal evolution, we interrogate a myelofibrosis patient cohort with longitudinal molecular evaluation and discover that ruxolitinib is associated with clonal outgrowth of RAS pathway mutations. Single-cell DNA sequencing combined with ex vivo treatment of RAS mutated CD34

Indexed as

Janus Kinase 2Janus Kinase InhibitorsMyeloproliferative DisordersPyrazolesras ProteinsAnimalsClonal EvolutionFemaleHumansMaleMiceMiddle AgedMutationNitrilesPrimary MyelofibrosisPyrimidinesJAK2 protein, humanJanus Kinase 2Janus Kinase InhibitorsNitrilesPyrazolesPyrimidinesras Proteinsruxolitinib

Identifiers

PMID40623967
PMCPMC12234676

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.